Mike Sharma: Adding Antiplatelets to Anticoagulation in AF Increases Harm Without Benefit
Mike Sharma, Senior Scientist at Population Health Research Institute, reposted from JAMA Neurology on LinkedIn:
”Adding antiplatelets to anticoagulation in the setting of AF results in hazard without benefit. Now we’ll established in multiple studies. Where we lack data is in short term use following a cerebrovascular event that may be atherosclerotic in origin in patients with coexisting AF.”
Quoting JAMA Neurology‘s post:
”Editorial: The ATIS-NVAF trial shows adding antiplatelet therapy to OAC in stroke patients with AF and atherosclerotic disease increases major bleeding without significant reduction in ischemic events.”
Read the full article here.
Title: Anticoagulation and Antiplatelet Therapy in Patients With Atrial Fibrillation and Atherosclerosis
Authors: Richard A. Bernstein, Lauren E. Previch
Stay updated with Hemostasis Today.
-
May 5, 2026, 16:28Nikolay Novitski: A New Era in Cardiovascular Prevention
-
May 5, 2026, 16:23Satyam Arora: Best Abstract Award in Pediatric Apheresis at ASFA 2026 Congress
-
May 5, 2026, 16:17Hannah Omunakwe: Your Sick Child Has a Clot. Did You See That Coming?
-
May 5, 2026, 15:57Venous Thromboembolism Risk in Pregnancy and the Postpartum Period – NBCA
-
May 5, 2026, 15:28Soumen Bhattacharyya: Hyperhomocysteinemia and Thrombosis – What Clinicians Should Know
-
May 5, 2026, 15:06Wolfgang Miesbach: How Should We Approach GI Angiodysplasia in VWD?
-
May 5, 2026, 14:48What Constitutes High Risk for Venous Thromboembolism? – JTH
-
May 5, 2026, 14:41How Real-Time Data, Rehabilitation Registries, and Patient-Reported Outcomes Can Transform Practice – European Stroke Organisation
-
May 5, 2026, 14:41Driving National Change for Bleeding Disorders – WFH